The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Subscribe To Our Newsletter & Stay Updated
